Jazz Pharmaceuticals plc (JAZZ) 13F Ownership Report (Q2 2026)

JAZZ ranks #853 out of 37503 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

JAZZ is a top-conviction position for Polaris Capital Management, LLC — at 7.5% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in JAZZ belongs to BlackRock, Inc., but the position matters far more to Polaris Capital Management, LLC, who has 7.5% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Fidelity has added to its JAZZ position for two straight quarters, increasing it by $974.6M to reach $1.1B today.

Sofinnova Investments, Inc. has trimmed its JAZZ position for two straight quarters, cutting it by $75.1M while still holding $88.0M.

JAZZ is down 2.8% today, but institutions show net buying of $3.5B this quarter — a divergence between today's price move and the underlying institutional flow.

JAZZ posted net income of $940.8M over the trailing twelve months, and currently trades at a P/E of 15.8.

• Profitable — net income of $940.8M over the trailing twelve months
• Revenue grew 12.6% year over year
• Net income improved year over year, from -$404.8M to $940.8M
• Generated $1.4B in positive operating cash flow
• Current ratio of 1.86x — enough short-term assets to cover short-term liabilities
• Liabilities run 2.70x equity — a highly leveraged balance sheet worth noting